

# Protocol

## Negative Pressure Wound Therapy in the Outpatient Setting

(10116)

<b>Medical Benefit</b>		<b>Effective Date:</b> 07/01/18	<b>Next Review Date:</b> 05/19
<b>Preauthorization</b>	No	<b>Review Dates:</b> 11/07, 09/08, 09/09, 09/10, 05/11, 05/12, 05/13, 05/14, 05/15, 05/16, 05/17, 05/18	

**Preauthorization is not required.**

*The following protocol contains medical necessity criteria that apply for this service. The criteria are also applicable to services provided in the local Medicare Advantage operating area for those members, unless separate Medicare Advantage criteria are indicated. If the criteria are not met, reimbursement will be denied and the patient cannot be billed. Please note that payment for covered services is subject to eligibility and the limitations noted in the patient's contract at the time the services are rendered.*

Populations	Interventions	Comparators	Outcomes
Individuals: • With diabetic lower-extremity ulcers or amputation wounds	Interventions of interest are: • Outpatient negative pressure wound therapy	Comparators of interest are: • Standard wound care	Relevant outcomes include: • Symptoms • Change in disease status • Morbid events • Quality of life • Treatment-related morbidity
Individuals: • With chronic pressure ulcers	Interventions of interest are: • Outpatient negative pressure wound therapy	Comparators of interest are: • Standard wound care	Relevant outcomes include: • Symptoms • Change in disease status • Morbid events • Quality of life • Treatment-related morbidity
Individuals: • With lower-extremity ulcers due to venous insufficiency	Interventions of interest are: • Outpatient negative pressure wound therapy	Comparators of interest are: • Compression therapy	Relevant outcomes include: • Symptoms • Change in disease status • Morbid events • Quality of life • Treatment-related morbidity
Individuals: • With burn wounds	Interventions of interest are: • Outpatient negative pressure wound therapy	Comparators of interest are: • Standard wound care	Relevant outcomes include: • Symptoms • Change in disease status • Morbid events • Quality of life • Treatment-related morbidity
Individuals: • With traumatic or surgical wounds	Interventions of interest are: • Outpatient negative pressure wound therapy	Comparators of interest are: • Standard wound care	Relevant outcomes include: • Symptoms • Change in disease status • Morbid events • Quality of life • Treatment-related morbidity

Populations	Interventions	Comparators	Outcomes
Individuals: <ul style="list-style-type: none"> <li>• With any wound type (acute or nonhealing)</li> </ul>	Interventions of interest are: <ul style="list-style-type: none"> <li>• Portable single-use outpatient negative pressure wound therapy</li> </ul>	Comparators of interest are: <ul style="list-style-type: none"> <li>• Standard negative pressure wound therapy</li> </ul>	Relevant outcomes include: <ul style="list-style-type: none"> <li>• Symptoms</li> <li>• Change in disease status</li> <li>• Morbid events</li> <li>• Quality of life</li> <li>• Treatment-related morbidity</li> </ul>

## DESCRIPTION

Negative pressure wound therapy (NPWT) involves the use of a negative pressure or suction device to aspirate and remove fluids, debris, and infectious materials from the wound bed to promote the formation of granulation tissue and wound healing.

## SUMMARY OF EVIDENCE

For individuals who have diabetic lower-extremity ulcers or amputation wounds who receive outpatient NPWT, the evidence includes RCTs and a systematic review of RCTs. Relevant outcomes are symptoms, change in disease status, morbid events, quality of life, and treatment-related morbidity. There was a higher rate of wound healing and fewer amputations with NPWT, although the studies were at risk of bias due to lack of blinding. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have chronic pressure ulcers who receive outpatient NPWT, the evidence includes RCTs and systematic reviews. Relevant outcomes are symptoms, change in disease status, morbid events, quality of life, and treatment-related morbidity. All trials are of low quality and at high risk of bias. Also, most study populations were treated in inpatient settings. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have lower-extremity ulcers due to venous insufficiency who receive outpatient NPWT, the evidence includes an RCT and a systematic review. Relevant outcomes are symptoms, change in disease status, morbid events, quality of life, and treatment-related morbidity. A single RCT in patients with nonhealing leg ulcers who were treated with skin grafts found a faster rate of healing with NPWT when used in the inpatient setting. No studies were identified on the effectiveness of NPWT as a primary treatment for leg ulcers or for the use of NPWT in the outpatient setting. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have burn wounds who receive outpatient NPWT, the evidence includes RCTs, systematic reviews, and case series. Relevant outcomes are symptoms, change in disease status, morbid events, quality of life, and treatment-related morbidity. An interim report of an RCT evaluating NPWT in partial-thickness burns, summarized in a Cochrane review, did not permit conclusions on the efficacy of NPWT for this indication. A separate RCT comparing NPWT with split-skin grafts in patients with full-thickness burns did not show differences in graft take and wound epithelialization. A retrospective case series reported functional outcomes for most patients who were treated with NPWT at a single center. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have traumatic or surgical wounds who receive outpatient NPWT, the evidence includes RCTs and systematic reviews. Relevant outcomes are symptoms, change in disease status, morbid events, quality of life, and treatment-related morbidity. There are limited data on NPWT as a primary treatment of partial-thickness burns. One RCT found no benefit of NPWT on graft take and wound epithelialization in patients with full-thickness burns. NPWT showed no benefit in the treatment of patients with surgical wounds or skin grafts

healing by primary intention, and a systematic review of NPWT for traumatic and surgical wounds found no differences between standard dressing and NPWT for any wound outcome measure. However, a small RCT has suggested that prophylactic NPWT may reduce the number of dressing changes and pain when used in an outpatient setting. A small retrospective study reported improved epithelialization with NPWT in patients free of comorbidities. Additional study in larger samples is needed to evaluate this outcome measure. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have any wound type (acute or nonhealing) who receive portable single-use outpatient NPWT, the evidence includes RCTs. Relevant outcomes are symptoms, change in disease status, morbid events, quality of life, and treatment-related morbidity. The evidence includes an RCT of the PICO Single Use Negative Pressure Wound Therapy System, an RCT of the nonpowered Smart Negative Pressure Wound Care System, and a pseudorandomized study of the Prevena Incision Management System. The PICO device was studied in an adequately powered but unblinded RCT of combined in- and outpatient use following total joint arthroplasty; also, a 2017 RCT compared the PICO device with standard dressing following abdominal surgery. Results showed some benefits, though not statistically significant. One study with the Smart Negative Pressure nonpowered Wound Care System showed noninferiority to a vacuum-assisted closure device. However, interpretation of this trial is limited by a high loss to follow-up and lack of a control group treated with dressings. These studies are insufficient to draw conclusions about its efficacy. Well-designed comparative studies with larger numbers of patients are needed to determine the effects of these technologies with greater certainty. The evidence is insufficient to determine the effects of the technology on health outcomes.

## POLICY

### INITIATION OF POWERED NEGATIVE PRESSURE WOUND THERAPY

An initial therapeutic trial of not less than two weeks using a powered negative pressure wound therapy (NPWT) system, as part of a comprehensive wound care program that includes controlling factors (e.g., diabetes, nutrition, relief of pressure) may be considered **medically necessary** in the following indications:

- Chronic (greater than 90 days) stage III or IV pressure ulcers that have failed to heal despite optimal wound care when there is high-volume drainage that interferes with healing and/or when standard dressings cannot be maintained due to anatomic factors; OR
- Wounds in patients with underlying clinical conditions that are known to negatively impact wound healing, which are non-healing (at least 30 days), despite optimal wound care. (Examples of underlying conditions include, but are not limited to diabetes, malnutrition, small vessel disease, and morbid obesity. Malnutrition, while a risk factor, must be addressed simultaneously with the NPWT); OR
- Traumatic or surgical wounds where there has been a failure of immediate or delayed primary closure AND there is exposed bone, cartilage, tendon, or foreign material within the wound.

### CONTINUATION OF POWERED NPWT

Continuation of the powered NPWT system, as part of a comprehensive wound care program, may be considered **medically necessary** following an initial therapeutic trial of not less than two weeks if the treatment trial has resulted in documented objective improvements in the wound, and if there is ongoing objective improvement during subsequent treatment. Objective improvements in the wound should include the development and presence of healthy granulation tissue, progressive wound contracture and decreasing depth, and/or the commencement of epithelial spread from the wound margins.

Continuation of the powered NPWT system is considered **not medically necessary** when any of the following occurs:

- The therapeutic trial or subsequent treatment period has not resulted in documented objective improvement in the wound, OR
- The wound has developed evidence of wound complications contraindicating continued NPWT, OR
- The wound has healed to an extent that either grafting can be performed or the wound can be anticipated to heal completely with other wound care treatments.

Therapeutic trials of powered NPWT systems for the treatment of other acute or chronic wounds except as noted above are considered **not medically necessary**.

Use of non-powered NPWT systems for the treatment of acute or chronic wounds is **investigational**.

### **POLICY GUIDELINES**

Contraindications to the use of NPWT systems include the following conditions as noted by a November 2009 U.S. Food and Drug Administration (FDA) alert: necrotic tissue with eschar, untreated osteomyelitis, nonenteric and unexplored fistulas, malignancy in the wound, exposed nerve, exposed anastomotic site, and exposed organ.

In a 2011 update, the FDA noted additional deaths and injury reports with NPWT since 2009. Although rare, these complications can occur wherever NPWT systems are used, including hospitals, long-term care facilities, and at home. Bleeding was the cause of the most serious adverse events, including deaths. Most reports of wound infection were related to the retention of dressing pieces in the wounds. FDA recommendations for healthcare providers include the following: select patients for NPWT carefully knowing that NPWT systems are contraindicated for certain wound types, and patient risk factors must be thoroughly considered before use; assure that the patient is monitored frequently in an appropriate care setting by a trained practitioner; be aware of complications associated with dressing changes such as infection and bleeding; be vigilant for potentially life-threatening complications, such as bleeding, and be prepared to take prompt action if they occur. The FDA reported that the safety and effectiveness of NPWT systems in newborns, infants and children has not been established at this time and currently, there are no NPWT systems cleared for use in these populations.

Continuation of healing during use of the NPWT system should be monitored on a frequency not less than every 14 days.

Complete healing of a wound would normally be anticipated if all bone, cartilage, tendons, and foreign material were completely covered, healthy granulation were present to within five mm of the surface, and the wound edges were reduced to two cm in width or diameter.

Powered NPWT systems should be used as part of a comprehensive wound care program that includes attention to other factors that impact wound healing such as diabetes control, nutritional status and relief of pressure.

The focus of these policy statements and guidelines is for use of NPWT in the outpatient setting.

### **MEDICARE ADVANTAGE**

For Medicare Advantage a NPWT pump and supplies are **medically necessary** when the following criterion is met:

The patient has a chronic Stage III or IV pressure ulcer\*, neuropathic (for example, diabetic) ulcer, venous or arterial insufficiency ulcer, or a chronic (being present for at least 30 days) ulcer of mixed etiology. A complete

wound therapy program described by criterion 1 and criteria 2, 3, or 4, as applicable depending on the type of wound, must have been tried or considered and ruled out prior to application of NPWT.

1. For all ulcers or wounds, the following components of a wound therapy program must include a minimum of all of the following general measures, which should either be addressed, applied, or considered and ruled out prior to application of NPWT:
  - a. Documentation in the patient's medical record of evaluation, care, and wound measurements by a licensed medical professional, and
  - b. Application of dressings to maintain a moist wound environment, and
  - c. Debridement of necrotic tissue if present, and
  - d. Evaluation of and provision for adequate nutritional status.
2. For Stage III or IV pressure ulcers:
  - a. The patient has been appropriately turned and positioned, and
  - b. The patient has used a support surface for pressure ulcers on the posterior trunk or pelvis, and
  - c. The patient's moisture and incontinence have been appropriately managed.
3. For neuropathic (for example, diabetic) ulcers:
  - a. The patient has been on a comprehensive diabetic management program, and
  - b. Reduction in pressure on a foot ulcer has been accomplished with appropriate modalities.
4. For venous insufficiency ulcers:
  - a. Compression bandages and/or garments have been consistently applied, and
  - b. Leg elevation and ambulation have been encouraged.
5. Surgically created wounds and traumatic wounds that met the following criteria in the inpatient setting and need treatment beyond discharge to the home setting: Complications of a surgically created wound (for example dehiscence) or a traumatic wound (for example, pre-operative flap or graft) where there is documentation of the medical necessity for accelerated formation of granulation tissue which cannot be achieved by other available topical wound treatments (for example, where other medical conditions of the patient will not allow for healing times achievable with other topical wound treatments).

If criterion above is not met, the NPWT pump and supplies are **not medically necessary**.

NPWT pumps need to be capable of accommodating more than one wound dressing set in the case when the patient has multiple wounds. In other words, it would be **not medically necessary** for more than one NPWT pump at a time.

An NPWT pump and supplies are **not medically necessary** for the following:

- Stage I or II pressure ulcers;
- The presence in the wound of necrotic tissue with eschar, if debridement is not attempted;
- Osteomyelitis within the vicinity of the wound that is not concurrently being treated with intent to cure;
- Cancer present in the wound;
- Active bleeding;
- The presence of an open fistula to an organ or body cavity within the vicinity of the wound.

Continued medical appropriateness:

For wounds and ulcers described above, once placed on an NPWT pump and supplies, in order to continue to be considered **medically necessary** a licensed medical professional must do the following:

1. On a regular basis:
  - a. directly assess the wound(s) being treated with the NPWT pump, and
  - b. supervise or directly perform the NPWT dressing changes, and
2. On at least a monthly basis, document changes in the ulcer's dimensions and characteristics.

If these criteria are not fulfilled, continued coverage of the NPWT pump is **not medically necessary**.

An NPWT pump and supplies are **not medically necessary** with any of the following, whichever occurs earliest:

- A) Continued medical appropriateness criteria are no longer met,
- B) In the judgment of the treating physician, adequate wound healing has occurred to the degree that NPWT may be discontinued,
- C) Any measurable degree of wound healing has failed to occur over the prior month. Wound healing is defined as improvement occurring in either surface area (length times width) or depth of the wound,
- D) Four (4) months (including the time NPWT was applied in an inpatient setting prior to discharge to the home) have elapsed using an NPWT pump in the treatment of the most recent wound,
- E) Once equipment or supplies are no longer being used for the patient, whether or not by the physician's order.

\* The staging of pressure ulcers used in this protocol is based on the National Pressure Ulcer Advisory Panel (NPUAP) Pressure Injury Stages.

## BACKGROUND

### CHRONIC WOUNDS

#### Management

The management and treatment of chronic wounds, including decubitus ulcers, is challenging. Most chronic wounds will heal only if the underlying cause (i.e., venous stasis, pressure, infection) is addressed. Also, cleaning the wound to remove nonviable tissue, microorganisms, and foreign bodies is essential to create the optimal conditions for either re-epithelialization (i.e., healing by secondary intention) or preparation for wound closure with skin grafts or flaps (i.e., healing by primary intention). Therefore, débridement, irrigation, whirlpool treatments, and wet-to-dry dressings are common components of chronic wound care.

NPWT involves the use of a negative pressure therapy or suction device to aspirate and remove fluids, debris, and infectious materials from the wound bed to promote the formation of granulation tissue. The devices may also be used as an adjunct to surgical therapy or as an alternative to surgery in a debilitated patient. Although the exact mechanism has not been elucidated, it is hypothesized that negative pressure contributes to wound healing by removing excess interstitial fluid, increasing the vascularity of the wound, reducing edema, and/or creating beneficial mechanical forces that lead to cell growth and expansion.

A nonpowered (mechanical) NPWT system has also been developed; the Smart Negative Pressure (SNaP) Wound Care System is portable and lightweight (three oz.) and can be worn underneath clothing. This system consists of a cartridge, dressing, and strap; the cartridge acts as the negative pressure source. The system is reported to generate negative pressure levels similar to other NPWT systems. This system is fully disposable.

The focus of this protocol is the use of NPWT in the outpatient setting. It is recognized that patients may begin using the device in the inpatient setting as they transition to the outpatient setting.

## REGULATORY STATUS

Negative pressure therapy or suction devices cleared by the FDA for treating chronic wounds include, but are not limited to: Vacuum Assisted Closure® Therapy (V.A.C., also known as negative pressure wound therapy; KCI); Versatile 1™ (V1) Wound Vacuum System (Blue Sky Medical), RENASYS™ EZ PLUS (Smith & Nephew), Foryou NPWT NP32 Device (Foryou Medical Electronics), and PICO Single Use Negative Pressure Wound Therapy System (Smith & Nephew).

Portable systems include the RENASYS™ GO (Smith & Nephew), XLR8 PLUS (Genadyne Biotechnologies), extriCARE® 2400 NPWT System (Devon Medical), the V.A.C. Via™ (KCI), and the PICO Single Use Negative Pressure Wound Therapy System (Smith & Nephew). The Prevena™ Incision Management System (KCI) is designed specifically for closed surgical incisions.

A nonpowered NPWT device, the SNaP® Wound Care System (Spiracur, acquired by Acclivity in 2015), is a class II device requiring notification to market but not having FDA premarket approval. In 2009, it was cleared for marketing by FDA through the 510(k) (K081406) and is designed to remove small amounts of exudate from chronic, traumatic, dehisced, acute, or subacute wounds and diabetic and pressure ulcers.

No NPWT device has been cleared for use in infants and children.

In November 2009, FDA issued an alert concerning complications and deaths associated with NPWT systems. An updated alert was issued in February 2011.<sup>1</sup>

FDA product code: OMP

## RELATED PROTOCOLS

Autologous Platelet-Derived Growth Factors for Wound Healing and Other Non-Orthopedic Conditions

Bioengineered Skin and Soft Tissue Substitutes

Electrostimulation and Electromagnetic Therapy for Treating Wounds

---

Services that are the subject of a clinical trial do not meet our Technology Assessment Protocol criteria and are considered investigational. *For explanation of experimental and investigational, please refer to the Technology Assessment Protocol.*

It is expected that only appropriate and medically necessary services will be rendered. We reserve the right to conduct prepayment and postpayment reviews to assess the medical appropriateness of the above-referenced procedures. **Some of this protocol may not pertain to the patients you provide care to, as it may relate to products that are not available in your geographic area.**

## REFERENCES

We are not responsible for the continuing viability of web site addresses that may be listed in any references below.



1. U.S. Food and Drug Administration. UPDATE on Serious Complications Associated with Negative Pressure Wound Therapy Systems: FDA Safety Communication. 2011 Feb; <https://wayback.archive-it.org/7993/20170406071858/https://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm244211.htm>. Accessed January 2, 2018.
2. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Vacuum-assisted closure in the treatment of chronic wounds. TEC Assessments. 2000;Volume 15:Tab 23.
3. Rhee SM, Valle MF, Wilson LM, et al. Negative Pressure Wound Therapy Technologies For Chronic Wound Care in the Home Setting. Evidence Report/Technology Assessment (Contract No. 290-201-200007-I) Rockville, MD: Agency for Healthcare Research and Quality; 2014.
4. Rhee SM, Valle MF, Wilson LM, et al. Negative pressure wound therapy technologies for chronic wound care in the home setting: A systematic review. *Wound Repair Regen*. Jul-Aug 2015;23(4):506-517. PMID 25845268
5. Sullivan N, Snyder DL, Tipton K, et al. Technology assessment: Negative pressure wound therapy devices (Contract No. 290-2007-10063). Rockville, MD: Agency for Healthcare Research and Quality; 2009.
6. Dumville JC, Hinchliffe RJ, Cullum N, et al. Negative pressure wound therapy for treating foot wounds in people with diabetes mellitus. *Cochrane Database Syst Rev*. Oct 17 2013;10(10):CD010318. PMID 24132761
7. Blume PA, Walters J, Payne W, et al. Comparison of negative pressure wound therapy using vacuum-assisted closure with advanced moist wound therapy in the treatment of diabetic foot ulcers: a multicenter randomized controlled trial. *Diabetes Care*. Apr 2008;31(4):631-636. PMID 18162494
8. Armstrong DG, Lavery LA. Negative pressure wound therapy after partial diabetic foot amputation: a multi-centre, randomised controlled trial. *Lancet*. Nov 12 2005;366(9498):1704-1710. PMID 16291063
9. Dalla Paola L, Carone A, Ricci S, et al. Use of vacuum assisted closure therapy in the treatment of diabetic foot wounds. *J Diabetic Foot Complications*. 2010;2:33-44. PMID
10. Dumville JC, Webster J, Evans D, et al. Negative pressure wound therapy for treating pressure ulcers. *Cochrane Database Syst Rev*. May 20 2015;5(5):CD011334. PMID 25992684
11. Wanner MB, Schwarzl F, Strub B, et al. Vacuum-assisted wound closure for cheaper and more comfortable healing of pressure sores: a prospective study. *Scand J Plast Reconstr Surg Hand Surg*. Mar 2003;37(1):28-33. PMID 12625392
12. Dumville JC, Land L, Evans D, et al. Negative pressure wound therapy for treating leg ulcers. *Cochrane Database Syst Rev*. Jul 14 2015;7(7):CD011354. PMID 26171910
13. Vuerstaek JD, Vainas T, Wuite J, et al. State-of-the-art treatment of chronic leg ulcers: A randomized controlled trial comparing vacuum-assisted closure (V.A.C.) with modern wound dressings. *J Vasc Surg*. Nov 2006;44(5):1029-1037; discussion 1038. PMID 17000077
14. Dumville JC, Munson C, Christie J. Negative pressure wound therapy for partial-thickness burns. *Cochrane Database Syst Rev*. Dec 15 2014;12(12):CD006215. PMID 25500895
15. Bloemen MC, van der Wal MB, Verhaegen PD, et al. Clinical effectiveness of dermal substitution in burns by topical negative pressure: a multicenter randomized controlled trial. *Wound Repair Regen*. Nov-Dec 2012;20(6):797-805. PMID 23110478
16. Runkel N, Krug E, Berg L, et al. Evidence-based recommendations for the use of Negative Pressure Wound Therapy in traumatic wounds and reconstructive surgery: steps towards an international consensus. *Injury*. Feb 2011;42 Suppl 1:S1-12. PMID 21316515
17. Ehrl D, Heidekrueger PI, Broer PN, et al. Topical negative pressure wound therapy of burned hands: functional outcomes. *J Burn Care Res*. Mar 31 2017. PMID 28368916
18. Webster J, Scuffham P, Stankiewicz M, et al. Negative pressure wound therapy for skin grafts and surgical wounds healing by primary intention. *Cochrane Database Syst Rev*. Oct 7 2014;10(10):CD009261. PMID 25287701
19. Dumville JC, Owens GL, Crosbie EJ, et al. Negative pressure wound therapy for treating surgical wounds healing by secondary intention. *Cochrane Database Syst Rev*. Jun 4 2015;6(6):CD011278. PMID 26042534



20. De Vries FE, Wallert ED, Solomkin JS, et al. A systematic review and meta-analysis including GRADE qualification of the risk of surgical site infections after prophylactic negative pressure wound therapy compared with conventional dressings in clean and contaminated surgery. *Medicine (Baltimore)*. Sep 2016;95(36):e4673. PMID 27603360
21. Stannard JP, Volgas DA, McGwin G, 3rd, et al. Incisional negative pressure wound therapy after high-risk lower extremity fractures. *J Orthop Trauma*. Jan 2012;26(1):37-42. PMID 21804414
22. Stannard JP, Robinson JT, Anderson ER, et al. Negative pressure wound therapy to treat hematomas and surgical incisions following high-energy trauma. *J Trauma*. Jun 2006;60(6):1301-1306. PMID 16766975
23. Monsen C, Acosta S, Mani K, et al. A randomised study of NPWT closure versus alginate dressings in perivascular groin infections: quality of life, pain and cost. *J Wound Care*. Jun 2015;24(6):252, 254-256, 258-250. PMID 26075373
24. Masden D, Goldstein J, Endara M, et al. Negative pressure wound therapy for at-risk surgical closures in patients with multiple comorbidities: a prospective randomized controlled study. *Ann Surg*. Jun 2012;255(6):1043-1047. PMID 22549748
25. Chio EG, Agrawal A. A randomized, prospective, controlled study of forearm donor site healing when using a vacuum dressing. *Otolaryngol Head Neck Surg*. Feb 2010;142(2):174-178. PMID 20115970
26. Biter LU, Beck GM, Mannaerts GH, et al. The use of negative-pressure wound therapy in pilonidal sinus disease: a randomized controlled trial comparing negative-pressure wound therapy versus standard open wound care after surgical excision. *Dis Colon Rectum*. Dec 2014;57(12):1406-1411. PMID 25380007
27. Danne J, Gwini S, McKenzie D, et al. A retrospective study of pilonidal sinus healing by secondary intention using negative pressure wound therapy versus alginate or gauze dressings. *Ostomy Wound Manage*. Mar 2017;63(3):47-53. PMID 28355137
28. Armstrong DG, Marston WA, Reyzelman AM, et al. Comparison of negative pressure wound therapy with an ultraportable mechanically powered device vs. traditional electrically powered device for the treatment of chronic lower extremity ulcers: a multicenter randomized-controlled trial. *Wound Repair Regen*. Mar-Apr 2011;19(2):173-180. PMID 21362084
29. Armstrong DG, Marston WA, Reyzelman AM, et al. Comparative effectiveness of mechanically and electrically powered negative pressure wound therapy devices: a multicenter randomized controlled trial. *Wound Repair Regen*. May-Jun 2012;20(3):332-341. PMID 22564228
30. Marston WA, Armstrong DG, Reyzelman AM, et al. A multicenter randomized controlled trial comparing treatment of venous leg ulcers using mechanically versus electrically powered negative pressure wound therapy. *Adv Wound Care (New Rochelle)*. Feb 1 2015;4(2):75-82. PMID 25713749
31. Lerman B, Oldenbrook L, Eichstadt SL, et al. Evaluation of chronic wound treatment with the SNaP wound care system versus modern dressing protocols. *Plast Reconstr Surg*. Oct 2010;126(4):1253-1261. PMID 20885246
32. Karlakki SL, Hamad AK, Whittall C, et al. Incisional negative pressure wound therapy dressings (iNPWTd) in routine primary hip and knee arthroplasties: A randomised controlled trial. *Bone Joint Res*. Aug 2016;5(8):328-337. PMID 27496913
33. Schwartz JA, Goss SG, Facchin F, et al. Single-use negative pressure wound therapy for the treatment of chronic lower leg wounds. *J Wound Care*. Feb 2015;24 Suppl 2:S4-9. PMID 25647506
34. O'Leary DP, Peirce C, Anglim B, et al. Prophylactic negative pressure dressing use in closed laparotomy wounds following abdominal operations: a randomized, controlled, open-label trial: The P.I.C.O. Trial. *Ann Surg*. Jun 2017;265(6):1082-1086. PMID 27926575
35. Grauhan O, Navasardyan A, Hofmann M, et al. Prevention of poststernotomy wound infections in obese patients by negative pressure wound therapy. *J Thorac Cardiovasc Surg*. May 2013;145(5):1387-1392. PMID 23111014
36. Pauser J, Nordmeyer M, Biber R, et al. Incisional negative pressure wound therapy after hemiarthroplasty for femoral neck fractures - reduction of wound complications. *Int Wound J*. Oct 2016;13(5):663-667. PMID 25125244

37. Vig S, Dowsett C, Berg L, et al. Evidence-based recommendations for the use of negative pressure wound therapy in chronic wounds: steps towards an international consensus. *J Tissue Viability*. Dec 2011;20 Suppl 1:S1-18. PMID 22119531
38. Willy C, Agarwal A, Andersen CA, et al. Closed incision negative pressure therapy: international multidisciplinary consensus recommendations. *Int Wound J*. Apr 2017;14(2):385-398. PMID 27170231
39. Hospenthal DR, Murray CK, Andersen RC, et al. Guidelines for the prevention of infections associated with combat-related injuries: 2011 update: endorsed by the Infectious Diseases Society of America and the Surgical Infection Society. *J Trauma*. Aug 2011;71(2 Suppl 2):S210-234. PMID 21814089
40. Lipsky BA, Berendt AR, Cornia PB, et al. 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. *J Am Podiatr Med Assoc*. Jan-Feb 2013;103(1):2-7. PMID 23328846
41. Qaseem A, Humphrey LL, Forciea MA, et al. Treatment of pressure ulcers: a clinical practice guideline from the American College of Physicians. *Ann Intern Med*. Mar 03 2015;162(5):370-379. PMID 25732279
42. Association for the Advancement of Wound Care (AAWC). Guideline of Pressure Ulcer Guidelines. 2010; <https://aawconline.memberclicks.net/assets/appendix%20c%20guideline%20icvug-textformatrecommendations-final%20v42%20changessaved18aug17.pdf>. Accessed January 2, 2018.
43. Association for the Advancement of Wound Care (AAWC). International Consolidated Venous Ulcer Guideline (ICVUG) 2015 (Update of AAWC Venous Ulcer Guideline, 2005 and 2010) 2015; [https://aawconline.memberclicks.net/assets/docs/appendix%20b-1\\_icvugevidencesummarytable-v66-18aug17%20-2.pdf](https://aawconline.memberclicks.net/assets/docs/appendix%20b-1_icvugevidencesummarytable-v66-18aug17%20-2.pdf). Accessed January 2, 2018.
44. National Institute for Health and Care Excellence (NICE). Negative Pressure Wound Therapy for the Open Abdomen [IPG467]. 2013; <https://www.nice.org.uk/guidance/ipg467>. Accessed January 2, 2018.
45. National Institute for Health and Care Excellence (NICE). Diabetic Foot Problems: Prevention and Management [NG19]. 2016; <https://www.nice.org.uk/guidance/ng19/evidence>. Accessed January 2, 2018.
46. National Institute for Health and Care Excellence (NICE). Pressure ulcers: prevention and management [CG179]. 2014; <https://www.nice.org.uk/guidance/cg179>. Accessed January 2, 2018.
47. National Pressure Ulcer Advisory Panel. NPUAP Pressure Injury Stages. 2016. <http://www.npuap.org/resources/educational-and-clinical-resources/npuap-pressure-injury-stages/> Accessed 03/16/18.
48. Noridian Healthcare Solutions, LLC, (Jurisdiction - New York - Entire State, Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, Vermont, District of Columbia, Delaware, Maryland, New Jersey, Pennsylvania, California - Entire State, American Samoa, Guam, Hawaii, Northern Mariana Islands, Nevada) Local Coverage Determination (LCD): Negative Pressure Wound Therapy Pumps (L33821), Revision Effective Date for services performed on or after 05/25/2017.
49. National Government Services, Inc. (Primary Geographic Jurisdiction - Illinois, New York - Entire State, Connecticut, Massachusetts, Maine, New Hampshire, Rhode Island, Vermont, Wisconsin, Minnesota) Local Coverage Determination (LCD): Outpatient Physical and Occupational Therapy Services (L33631), Revision Effective Date for services performed on or after 01/01/2018.